Silexion Therapeutics CORP (SLXNW) — 8-K Filings

All 8-K filings from Silexion Therapeutics CORP. Browse 37 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (37)

Silexion Therapeutics Corp. Files 8-K — Dec 16, 2025 Risk: medium
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 16, 2025. The filing indicates a change in the company's name and potentially
Silexion Therapeutics Files 8-K — Dec 2, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 2, 2025, reporting under Regulation FD and including financial statements and
Silexion Therapeutics Files 8-K — Nov 25, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on November 25, 2025, reporting under Regulation FD and including financial statements an
Silexion Therapeutics Files 8-K — Sep 30, 2025 Risk: low
Silexion Therapeutics Corp. filed an 8-K on September 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, form
Silexion Therapeutics Corp. Files 8-K for Material Agreement — Sep 26, 2025 Risk: medium
Silexion Therapeutics Corp. (formerly Biomotion Sciences) entered into a material definitive agreement on September 26, 2025. The company, incorporated in the C
Silexion Therapeutics to Acquire 03 Life Sciences — Sep 25, 2025 Risk: medium
Silexion Therapeutics Corp. announced on September 23, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Scienc
Silexion Therapeutics Reports Equity Issuance — Sep 15, 2025 Risk: medium
Silexion Therapeutics Corp. reported on September 15, 2025, regarding unregistered sales of equity securities and other events. The company, formerly known as B
Silexion Therapeutics Corp. Files Material Definitive Agreement — Sep 12, 2025 Risk: medium
Silexion Therapeutics Corp. entered into a material definitive agreement on September 11, 2025. The company, formerly known as Biomotion Sciences, is incorporat
Silexion Therapeutics Files 8-K — Sep 11, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 11, 2025, reporting under Regulation FD and including financial statements a
Silexion Therapeutics Corp. Files 8-K — Sep 4, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 4, 2025, reporting on events that occurred on the same date. The filing indi
Silexion Therapeutics Files 8-K — Sep 2, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 2, 2025, reporting on events as of the same date. The filing indicates the c
Silexion Therapeutics Files 8-K — Aug 20, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on August 20, 2025, reporting other events and financial statements. The company, incorpo
Silexion Therapeutics Files 8-K with Corporate Updates — Aug 19, 2025 Risk: low
Silexion Therapeutics Corp. filed an 8-K on August 19, 2025, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote
Silexion Therapeutics Files 8-K: Agreements & Equity Sales — Aug 1, 2025 Risk: medium
Silexion Therapeutics Corp. (formerly Biomotion Sciences) reported on August 1, 2025, regarding a material definitive agreement, unregistered sales of equity se
Silexion Therapeutics to be Acquired by 03 Life Sciences — Jul 29, 2025 Risk: medium
Silexion Therapeutics Corp. announced on July 29, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is e
Silexion Therapeutics Faces Delisting Notice — Jul 21, 2025 Risk: high
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on July 21, 2025, reporting a notice of delisting or failure to satisfy a continued listi
Silexion Therapeutics Files 8-K, Former Biomotion Sciences — Jul 16, 2025 Risk: low
Silexion Therapeutics Corp. filed an 8-K on July 16, 2025, reporting on other events and financial statements. The company, formerly known as Biomotion Sciences
Silexion Therapeutics Files 8-K on Shareholder Vote Matters — Jul 14, 2025 Risk: low
Silexion Therapeutics Corp. filed an 8-K on July 14, 2025, reporting on a submission of matters to a vote of security holders. The company, formerly known as Bi
Silexion Therapeutics Files 8-K — Jul 9, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on July 9, 2025, reporting on its ordinary shares and warrants. The company, incorporated
Silexion Therapeutics Raises $1.3M in Share Sale — Jun 3, 2025 Risk: medium
Silexion Therapeutics Corp. announced on June 3, 2025, that it has entered into a securities purchase agreement. The agreement involves the sale of 1,150,000 or
Silexion Therapeutics Files 8-K on Share and Warrant Activity — May 29, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on May 29, 2025, reporting on events related to its ordinary shares and warrants. The com
Silexion Therapeutics Receives NASDAQ Delisting Notice — May 23, 2025 Risk: high
Silexion Therapeutics Corp. announced on May 23, 2025, that it received a notice from NASDAQ on May 22, 2025, indicating a failure to meet a continued listing r
Silexion Therapeutics Files 8-K — May 21, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on May 21, 2025, reporting on financial statements and exhibits. The company, incorporate
Silexion Therapeutics Files 8-K with Financials — Apr 23, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on April 23, 2025, reporting on financial statements and exhibits. The company, incorpora
Silexion Therapeutics Files 8-K, Notes Warrants — Mar 28, 2025 Risk: low
Silexion Therapeutics Corp. filed an 8-K on March 28, 2025, reporting on other events and financial statements. The company, formerly known as Biomotion Science
Silexion Therapeutics Corp. Files 8-K for Material Definitive Agreement — Mar 14, 2025 Risk: medium
Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on March 14, 2025, that it entered into a material definitive agreement. The company, incorp
Silexion Therapeutics Files 8-K with Financials & Warrants — Mar 5, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on March 5, 2025, reporting on financial statements and exhibits. The company, incorporat
Silexion Therapeutics Corp. Files 8-K: Material Agreement & Equity Sales — Jan 30, 2025 Risk: medium
On January 29, 2025, Silexion Therapeutics Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securit
Silexion Therapeutics Files 8-K on Warrants — Jan 28, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on January 28, 2025, that it has filed a Form 8-K. The company, incorporated in the Cayman I
Silexion Therapeutics Corp. Enters Material Definitive Agreement — Jan 17, 2025 Risk: medium
On January 15, 2025, Silexion Therapeutics Corp. entered into a material definitive agreement. The company, formerly known as Biomotion Sciences until May 6, 20
Silexion Therapeutics Corp. Files 8-K — Jan 15, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on January 15, 2025, reporting on its corporate actions. The company, incorporated in the
Silexion Therapeutics Files 8-K on Financials — Jan 14, 2025 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on January 14, 2025, reporting on its results of operations and financial condition. The
Silexion Therapeutics Files 8-K on Shares and Warrants — Dec 17, 2024 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 17, 2024, reporting on ordinary shares and warrants. The company, incorporate
Silexion Therapeutics Announces Warrant Exercise Agreement — Dec 16, 2024 Risk: low
Silexion Therapeutics Corp. announced on December 16, 2024, that it has entered into a warrant exercise agreement. This agreement allows for the exercise of war
Silexion Therapeutics Appoints New CMO, Board Member — Dec 10, 2024 Risk: medium
On December 10, 2024, Silexion Therapeutics Corp. announced the appointment of Dr. Yaron Paz as Chief Medical Officer and Dr. Shimon Eckhouse as a new board mem
Silexion Therapeutics Corp. Files 8-K for Security Holder Rights — Nov 29, 2024 Risk: medium
Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on November 27, 2024, a material modification to the rights of its security holders. This fi
Silexion Therapeutics Files 8-K on Warrants — Nov 27, 2024 Risk: low
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on November 27, 2024, reporting on warrants exercisable for ordinary shares at $1.150 per

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX